Profile: Axonics Modulation Technologies Inc (AXNX.OQ)
Axonics Modulation Technologies, Inc. is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR.
The Company has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, which typically lasts a few days to a few weeks, and a permanent implant for those patients who experience a successful external trial period. Its r-SNM System includes two implantable components and two external components. Implantable components includes rechargeable implantable pulse generator (IPG), which is a five cubic centimeters and provides two weeks of battery life between charges under normal use conditions and tined four-electrode lead, which delivers current-controlled stimulation to the targeted sacral nerve. External components include wireless charging device, which allows transcutaneous charging of the IPG and wireless remote control that communicates with the device at a range of up to approximately three feet.
The Company competes with Medtronic plc and Allergan plc.
Axonics Modulation Technologies Inc
26 Technology Dr
IRVINE CA 92618-2380